In total, Denmark-based Novo Nordisk has filed 21 lawsuits against medical spas, weight loss clinics and compounding pharmacies. The drugmaker accused these companies of selling illegal versions of semaglutide — the active ingredient of Ozempic, Rybelsus and Wegovy — that contain “known impurities and the presence of unknown impurities,” Novo Nordisk said in a May 30 statement.
Ozempic and Rybelsus are approved for Type 2 diabetes, and Wegovy is indicated for chronic weight management and serious cardiovascular events. All are blockbuster therapies, costing the U.S. healthcare system $38.6 billion in 2023.
Novo Nordisk said it does not sell bulk semaglutide to compounding pharmacies or any other entity. The company also does not contract external manufacturers to make the medications.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.